AUDIO-Medco eyes expansion in Europe to fuel long-term growth

November 15, 2007


With at least $60 billion in U.S. annual sales of brand name medicines going off patent between now and 2012 — Medco is in a sweet spot.

The question on investors’ minds? What will spur growth beyond the generic windfall five years out? CEO David Snow told the Reuters Health Summit expansion plans in Europe will be one of those drivers, and said talks are going on right now.

No comments so far

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see